Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 21, 2024, serves as a transaction notification for the month of August 2024. The report discloses a specific transaction involving a Person Discharging Managerial Responsibilities (PDMR) under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single executive compensation event.
- Instrument: American Depositary Shares (ADSs) (ISIN: US37733W2044)
- Transaction Type: Vesting of deferred investment award (25% of an award made on August 19, 2019)
- Volume: 2,385.035 notional ADSs
- Price: $41.5200 per ADS
- Settlement: Cash payment of $99,026.66 (less applicable tax withholding)
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a routine vesting event for an executive officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Executive Involved: Shobie Ramakrishnan, Chief Digital and Technology Officer.
- Transaction Date: August 19, 2024.
- Nature of Event: Vesting of 25% of a 2019 deferred award, resulting in a cash payout rather than share issuance.
- Valuation: The transaction utilized a price of $41.52 per ADS.